3 unknown, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow PD-L1 inhibitor: new trials by email Literature Review of PD-L1 inhibitor trials Research Report on PD-L1 inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Advanced Refractory Solid Tumors | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Soochow University | 40 | 2025-12-27 | 2026-01-08 |
| Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI) - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Recruiting | Peking University Cancer Hospital & Institute | 65 | 2025-02-25 | 2025-03-11 | |
| HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC PD-L1 inhibitor, HAIC - ICC, Advanced Cancer | Phase 2 | Recruiting | Eastern Hepatobiliary Surgery Hospital | 50 | 2025-01-01 | 2026-01-23 |
| PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Metastatic Solid Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 56 | 2022-09-01 | 2022-09-07 |
| Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy PD-1 inhibitor - Transitional Cell Tumor, Hepatoblastoma | Phase 2 / Phase 3 | Unknown | RenJi Hospital | 15 | 2022-04-10 | 2022-04-11 |
| PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer PD-L1 inhibitor - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2022-04-01 | 2022-04-13 |
| Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group Chemotherapy, Radiation, Durvalumab - Anal Cancer, Anal Carcinoma | Phase 2 | Active not recruiting | Goethe University | 180 | 2020-01-07 | 2026-08-14 |
Anus Neoplasms (1) · Hepatoblastoma (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1)
Second Affiliated Hospital of Soochow University (2) · Eastern Hepatobiliary Surgery Hospital (1) · Goethe University (1) · Peking University Cancer Hospital & Institute (1) · RenJi Hospital (1) · The Affiliated Hospital of Qingdao University (1)
China (4) · Austria (1) · Germany (1) · Switzerland (1)
Hao Feng (1) · Qiang Xia (1) · Xiaochun Zhang, Prof (1)
2018 (1)